Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9408522 | 0.98 | SLC6A4 (0.42) | DPP4AKR1C1GRIN2DGRIN3BCYP2B6 | |
| SCHEMBL18297676 | 0.91 | OPRM1 (0.39) | DPP4OPRM1MEN1KMT2A | |
| SCHEMBL14610968 | 0.81 | OPRM1 (0.55) | SLC6A4KCNH2OPRM1MEN1ALDH1A1 | |
| SCHEMBL28545379 | 0.79 | CYP2C9 (0.38) | SLC6A2SLC6A4SLC6A3SIGMAR1NPC1 | |
| SCHEMBL7450867 | 0.77 | AKR1C1 (0.47) | DPP4AKR1C1GRIN2DGRIN3BCYP2B6 | |
| SCHEMBL56575 | 0.77 | NPC1 (0.57) | OPRM1OPRD1MEN1NPC1ALDH1A1 | |
| SCHEMBL7214379 | 0.77 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL31147216 | 0.77 | POLB (0.38) | SLC6A4SLC6A3OPRM1OPRD1MEN1 | |
| SCHEMBL181145 | 0.76 | NPC1 (0.55) | OPRM1OPRD1MEN1NPC1ALDH1A1 | |
| SCHEMBL18768887 | 0.76 | NPC1 (0.55) | OPRM1OPRD1MEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511721-B | Special organic silicon adhesive for display lamination and preparation method thereof | 复旦大学 | 2021-04-02 | — | — | CN | claimed |
| US-9023864-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2492267-B1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | MERCK SHARP & DOHME (US) | 2014-11-26 | — | — | EP | disclosed |
| CN-102333771-B | Indole derivatives as crth2 receptor antagonists | MERCK SHARP & DOHME | 2014-03-19 | — | — | CN | disclosed |
| EP-2401269-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20130150398-A1 | Indole Derivatives as CRTH2 Receptor Antagonists | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
| US-8394819-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2492267-A1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | disclosed |
| CN-102333771-A | Indole derivatives as crth2 receptor antagonists | MERCK SHARP & DOHME | 2012-01-25 | — | — | CN | disclosed |
| EP-2401269-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-16 | — | — | US | disclosed |
| WO-2010099039-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150398-A1 | Indole Derivatives as CRTH2 Receptor Antagonists | PTGER2, PTGDR2, PTGDR | DPP4 4221/4885AKR1C1 590/4885GRIN2D 523/4885 |
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | DPP4 4221/4885AKR1C1 590/4885GRIN2D 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.